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Abstract 26 
Inhibition of the over-activated alternative complement pathway in 27 
autosomal dominant polycystic kidney disease (ADPKD) retards disease 28 
progression in animal models, however it remains unknown how 29 
complement factor B (CFB) is up-regulated in ADPKD. Here we showed 30 
that the overexpression of complement factor B (CFB) in cystic kidneys 31 
associated with increased JAK2/STAT1 activity and enhanced expression of 32 
polycystin-1 C-terminal tail (PC1-CTT). Overexpression or blockage of 33 
STAT1 increased or decreased CFB expression and CFB promoter activity.  34 
Moreover, overexpression of PC1-CTT induced JAK2/STAT1 activation and 35 
CFB up-regulation in renal tubular epithelial cells. Furthermore, PC1-CTT 36 
over-expression increased human CFB promoter activity, whereas dominant 37 
negative STAT1 plasmids or mutation of putative STAT1 responsive 38 
elements decreased PC1-CTT induced CFB promoter activity. The effect of 39 
CFB on macrophage differentiation was tested on a mouse macrophage cell 40 
line. Bioactive CFB dose-dependently promoted macrophage M2 phenotype 41 
conversion. In addition, conditioned media from renal epithelial cells 42 
promoted macrophage M2 phenotype conversion which was blocked by 43 
STAT1 inhibition in a dose-dependent manner. Conditioned media from 44 
PC1-CTT transfected renal epithelial cells further promoted macrophage M2 45 
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phenotype conversion, which was suppressed by fludarabine or CFB 46 
antibody. In addition, we show that NF-κB acts downstream of PC1-CTT 47 
and may partly mediate PC1-CTT induced CFB expression. In conclusion, 48 
our study reveals possible mechanisms of CFB up-regulation in ADPKD and 49 
a novel role of PC1-CTT on ADPKD associated inflammation. Furthermore 50 
our study suggests that targeting STAT1 may be a new strategy to prevent 51 
inflammation in the kidney of patients with ADPKD.   52 
 53 
54 
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Introduction 55 
Autosomal dominant polycystic kidney disease (ADPKD) is one of the 56 
leading causes of end stage renal failure (21). Most cases of ADPKD (85%) 57 
are caused by mutations in the PKD1 gene which encodes polycystin-1. 58 
Polycystin-1 is a large transmembrane protein containing a ~200 amino-acid 59 
cytoplasmic tail which can be cleaved into a full-length 30 kD peptide and a 60 
half-length 15 kD peptide upon mechanical stimulation (4, 18). The 30 kD 61 
peptide (PC1-CTT) is over-expressed in ADPKD and non-orthologous 62 
models of polycystic kidney disease (PKD) (18). PC1-CTT plays important 63 
roles in cell proliferation, apoptosis and polarity (2, 8, 18). Moreover 64 
over-expression of PC1-CTT induced renal cysts in the zebrafish model (9). 65 
As a co-transcriptional factor, PC1-CTT regulates multiple downstream 66 
signaling pathways such as the Janus kinase (JAK)-signal transducer and 67 
activator of transcription (STAT) pathway (18). The JAK2/STAT1 pathway 68 
plays multiple roles in tumor genesis (1, 5). Among STAT family members, 69 
only STAT1, STAT3 and STAT6 have been studied in the field of PKD (19). 70 
STAT3 and STAT6 displayed proliferative and pro-cystic effects in animal 71 
models of PKD (10, 17). In vitro studies showed that STAT1 mediates 72 
polycystin-1 induced cell cycle arrest, however STAT1 promotes tumor 73 
growth mainly through its pro-inflammatory property, but this has not yet 74 
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been studied in PKD (1, 3, 5). 75 
 76 
The role of inflammation in polycystic kidney disease has gained increasing 77 
attention in recent years (16). Inflammatory cells such as macrophages 78 
accumulate in polycystic kidney tissues in proximity to renal cysts and 79 
differentiate into an M2-phenotype. This could be triggered by undefined 80 
soluble factors which are secreted by the cystic epithelium (15).  81 
 82 
We have previously shown that the alternative complement pathway is 83 
aberrantly activated in polycystic kidney disease, and that rosmarinic acid 84 
retards PKD progression. This is associated with decreased complement 85 
factor B (CFB) expression and reduced infiltration of macrophages (13, 14). 86 
However the underlying mechanisms of alternative complement pathway 87 
activation in polycystic kidneys in PKD remain unclear. 88 
 89 
The purpose of this study was to explore the mechanism of CFB 90 
overexpression in PKD and to investigate whether polycystin-1 regulates 91 
CFB expression. 92 
93 
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Materials and Methods  94 
Reagents and Plasmids 95 
The 712 bp human CFB promoter was sub-cloned into the pGL3-basic 96 
luciferase reporter vector. The site mutation of STAT1 response element on 97 
the CFB promoter plasmid was made using Fast mutagenesis system 98 
(Transgen, Beijing China). The 6-fold repeated GAS (5’-TTCCGGGAA-3’) 99 
sequence and 6-fold repeated and mutated GAS (5’- CGTACGGCT-3’) 100 
sequence were constructed on pGL3-basic vector. The vector pRL-TK was 101 
obtained from Promega (Madison, WI). PC1-CTT, DN-1-STAT1 (mutation 102 
at Y701F) and DN-2-STAT1 (mutation at S727A) plasmids were obtained 103 
from Addgene (18, 20). STAT1 was sub-cloned into pCDNA4/TO-myc-His 104 
vector. 105 
 106 
Total STAT1 (#9172), p-JAK2 (#3776), and p-STAT1 (#7649) antibodies are 107 
from Cell Signaling Technology (Beverly, MA, USA). GAPDH antibody 108 
(sc-365062), PC1 C-terminal antibody (sc-10371), control rabbit IgG 109 
(sc-2027) are from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and 110 
anti-myc from Abmart (#M20002, Shanghai, China). The CFB antibodies 111 
are from Proteintech (10170-1-AP) (Chicago, USA) and Santa Cruz (H95, 112 
sc-67141). Arginase-1 (ab60176) and iNOS (ab3523) antibodies are from 113 
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Abcam (Cambridge, UK). The STAT1 specific inhibitor fludarabine (S1491) 114 
and the NF-κB specific inhibitor QNZ were obtained from Selleckchem 115 
(Houston, TX, USA). Bioactive human CFB was purchased from Hycult 116 
biotech (Uden, Netherlands). IL-4 (#241-14) and IL-13 (#210-13) were from 117 
PeproTech (Rocky Hill, NJ, USA). INF-γ (Gibco, PMC4031) was bought 118 
from Invitrogen (USA). 119 
 120 
Animal and Human Samples 121 
Rat kidney tissues were collected from the Han: SPRD rat colony 122 
established in our animal facility from a litter which was obtained from Prof. 123 
Wuthrich (University of Zurich). Rats were kept according to local 124 
regulation and guidelines. Tissue samples from anonymous ADPKD patients 125 
and normal controls were obtained from Shanghai Changzheng Hospital. 126 
Informed consent was obtained from all participants. 127 
 128 
Cell culture and transfection 129 
Pkd1+/– and Pkd1–/– cells were obtained from Dr. Yiqiang Cai (Yale 130 
University) (6). Human immortalized renal epithelial cells (UCL93) were 131 
kindly provided by Prof. A.C. Ong (University of Sheffield, Sheffield, UK) 132 
(11). Cells were cultured to 70–80% confluence and transfected using 133 
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Ronfect reagent (Ronbio, Shanghai, China) according to the manufacturer’s 134 
instructions, for 48 hr before protein extraction. 135 
 136 
Protein Extraction and Western blot analysis 137 
Snap frozen kidney tissue was homogenized in freshly made tissue protein 138 
extraction reagent (T-PER, Pierce Bioscience, Rockford, IL). Homogenates 139 
were centrifuged, and supernatants were stored at -80 °C. 140 
 141 
To extract cell protein, cultured cells were washed and lysed in the same way. 142 
Lysates in SDS-sample buffer were boiled for 5 minutes at 95oC and equal 143 
protein amounts were resolved by SDS-PAGE gels before transferring to a 144 
PVDF membrane. The membrane was probed with first antibody by 145 
overnight incubation at 4° C, and thereafter with a secondary antibody by 146 
incubation for 2 hr at room temperature. Proteins of interest were and then 147 
visualized by enhanced chemiluminescence detection reagents. The average 148 
densitometry values from three independent experiments were measured. 149 
Since the blot probed with polycstin-1 antibody had a high background when 150 
using the standard protocol, we used a lower dilution of the first antibody 151 
(1:4000) and the second antibody (1:5000). In addition, the blot was 152 
incubated with the second antibody for only 2 hr at 4° C before 153 
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visualization. 154 
 155 
Immunohistochemical analysis 156 
Immunhistochemistry was performed on paraffin sections of formalin-fixed 157 
tissues (3 μm thick). Sections were incubated overnight at 4 oC with primary 158 
antibody against p-JAK2 (1:100, Abcam, ab32101), p-STAT1 (1:100, 159 
Affinity, AF3299), CFB antibody (1:100, Proteintech, 10170-1-AP) and PC1 160 
C-terminal antibody (1:200, Santa cruz, sc-10371). Signals were detected 161 
using Dako EnVision Detection Systems Peroxidase/DAB, Rabbit/Mouse 162 
(K5007). Micrographs were made randomly using the x400 magnification of 163 
the light microscope. 164 
 165 
Dual-Luciferase Reporter Assay 166 
UCL93 cells were cultured to 70–80% confluency in 48-well plate and using 167 
Ronfect transfection reagent according to manufacturer’s instructions, using 168 
25 ng reporter construct, 25 ng pRL-TK plasmid and 50 ng expression 169 
plasmid, then cultured for 24 hr in starve medium. A dual-luciferase reporter 170 
assay system (Promega) was used for measurements of firefly and Renilla 171 
luciferase activities. At least three independent transfections were performed, 172 
and all analyses were performed in quadruplicate. The average values in 173 
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each experiment were measured. 174 
 175 
Chromatin immunoprecipitation (ChIP) assay 176 
ChIP assay was conducted using the Beyotime-ChIP Assay Kit, according to 177 
the manufacturer’s protocol (P2078, Beyotime, Nanjing China). 178 
Immunoprecipitation was performed with the anti-total STAT1 antibody. 179 
Two PCR primer pairs were designed with one containing a putative 180 
STAT-binding site, the other primer pair spans -712/-373 region representing 181 
a non-specific region of CFB promoter. PCR products were analyzed by 182 
2.5 % agarose/ethidium bromide gel electrophoresis. 183 
 184 
In vitro macrophage differentiation assay 185 
UCL93 cells were cultured in DMEM/F12 medium containing 2% FBS in 186 
6-well plate. Medium was changed 16hr after transfection or fludarabine 187 
treatment, then cells were cultured for another 24hr with starvation medium. 188 
In some experiments, the STAT1 inhibitor fludarabine was added 6hr after 189 
transfection and medium was changed 16hr after transfection. Cell free 190 
supernatants was named conditioned medium (CM) and stored in aliquots at 191 
– 80 o C. 192 
 193 
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Approximately 1×106 RAW264.7 cells were cultured in 2% FBS medium in 194 
6-well plate overnight before experiments. The CM from UCL93 cells was 195 
used to treat mouse RAW264.7 cells. In some experiments, bioactive human 196 
CFB or CFB antibodies were added in un-conditioned medium or 197 
conditioned medium as indicated elsewhere. As positive controls, 100 μg/ml 198 
IL-4/IL-13 or 100 ng/ml INF-γ was added into un-conditioned medium to 199 
induce macrophage differentiation. After 24hr of treatment, protein was 200 
extracted and probed for iNOS and arginase-1 using Western blot as 201 
described above. 202 
 203 
Real-Time PCR 204 
Total RNA was extracted using RNase mini kit (Invitrogen, Carlsbad, CA, 205 
USA) and reverse-transcribed. The primer sequences were: 206 
Arg1, forward, 5'-CTCCAAGCCAAAGTCCTTAGAG; reverse, 5'- 207 
GGAGCTGTCATTAGGGACATC; iNOS, forward, 5'- 208 
GTTCTCAGCCCAACAATACAAGA; reverse, 5'- 209 
GTGGACGGGTCGATGTCAC; Mrc1, forward, 5'- 210 
CTCTGTTCAGCTATTGGACGC; reverse, 5'- 211 
CGGAATTTCTGGGATTCAGCTTC; GAPDH, forward, 5'- 212 
AGAACATCATCCCTGCATCC; reverse, 5'- 213 
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ATACCAGGAAATGAGCTTGAC; real-time PCR was performed using 214 
SYBR Green PCR Master Mix (Toyobo, Osaka, Japan) and 215 
Rotor-Gene-3000A real-time PCR system (Corbett, Sydney, Australia), 216 
according to the manufacturer’s protocol. In brief, the PCR amplification 217 
reaction mixture (25 μl) contained 1 μl cDNA, 0.4 mM sense and antisense 218 
primer, and 12.5 μl SYBR Green I. After initial denaturation at 95° C for 1 219 
min, the reaction was cycled 45 times. Each cycle consisted of denaturation 220 
at 95 °C for 15 s, primer annealing and extension at 60 °C for 31 s. The 221 
results are given as relative expression of Arg1, iNOS, Mrc1 normalized to 222 
the expression of GAPDH. Real-time PCR was done in triplicate for each 223 
experiment, and the average values were measured. Each experiment was 224 
repeated three times.   225 
 226 
Statistical Analysis 227 
Statistical analyses were performed by unpaired t-test or one-way ANOVA 228 
with the Newman-Keuls post hoc test using GraphPad Prism version 5.0 229 
(GraphPad, San Diego, CA). All data are expressed as means ± SD, and P < 230 
0.05 was considered as statistically significant. 231 
 232 
 233 
234 
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Results: 235 
1. CFB overexpression correlates with PC1-CTT overexpression and 236 
JAK/STAT1 activation in polycystic kidney tissues 237 
Figure 1A and 1B show that CFB was up-regulated in human and rat cystic 238 
kidney tissues which was correlated with increased p-JAK2, p-STAT1 and 239 
PC1 C-terminal tail (PC1-CTT).  240 
Immunohistochemistry was performed on rat kidney tissues to confirm the 241 
finding by Western blot. Figure 1C shows that signals for p-JAK2, p-STAT1, 242 
CFB and PC1-CTT were enhanced in Cy/+ cystic kidneys, where a similar 243 
expression pattern was found for these proteins. All these proteins were 244 
strongly stained in dilated tubules and small cysts but were weakly stained in 245 
large cysts. 246 
Since the specificity of the commercially available polycystin-1 antibody for 247 
PC1-CTT has not been reported, we performed two experiments to test its 248 
specificity. Figure 2A shows that PC1-CTT can be detected by this 249 
polycystin-1 antibody in Pkd1+/- cells but not Pkd1-/- cells. Moreover, 250 
overexpression of exogenous PC1-CTT could be detected by the 251 
polycystin-1 antibody and also by the myc-tag antibody (Figure 2B). 252 
 253 
2. STAT1 regulates CFB expression 254 
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To determine whether STAT1 regulates CFB expression in renal epithelial 255 
cells, we over-expressed STAT1 plasmids in UCL93 immortalized human 256 
renal epithelial cells. Figure 3A shows that overexpression of STAT1 257 
increased CFB expression as compared to control cells which were 258 
transfected with empty vectors. Moreover, the STAT1 inhibitor fludarabine 259 
dose-dependently reduced CFB expression which was correlated with 260 
decreased p-STAT1 levels (Figure 3B).  261 
 262 
The putative STAT1-binding site TTCCGAGAA was identified in the 263 
promoter sequence of the human CFB gene, at position -219 to -210 264 
upstream of translation start site (Figure 4A). STAT1 gene, CFB promoter 265 
(CFB-pr) and renilla were co-transfected in renal epithelial cells and were 266 
assayed for luciferase activity. Renilla values obtained were used for 267 
normalization of CFB promoter activity. Empty vector, CFB-pr and renilla 268 
co-transfected cells were used as control. STAT1 transfection leads to a 6 269 
fold increase in promoter activity (Figure 4B). Luciferase activity did not 270 
increase in cells transfected with STAT1 binding site mutated CFB promoter 271 
(CFB-pr-Mut) (Figure 4B). It is known that the gamma interferon activation 272 
site (GAS) sequence contains a STAT1 binding site (7). Thus we designed a 273 
reporter gene containing 6 repeated GAS sequences (GAS 274 
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5’-TTCCGGGAA-3’) and another reporter gene containing 6 mutated and 275 
repeated GAS sequences (GAS mutation 5’-CGTACGGCT). In Figure 4C, 276 
we show that CFB reporter gene and GAS reporter gene have similar 277 
responses to STAT1 stimulation, and that the GAS mutation abolished the 278 
response of GAS reporter gene to STAT1 stimulation.  279 
 280 
To confirm the direct association of the STAT1 protein with human CFB 281 
promoter, we performed chromatin immunoprecipitation (ChIP) assays. The 282 
PCR primer pair 1 was designed to flank the potential STAT1 site (-382 to 283 
-138), and we observed that the STAT1 protein level was increased in this 284 
region in STAT1 over-expressed 293T cells compared to empty vector 285 
transfected control cells. The second selected region (−712 to −373) was 286 
amplified by the primer pair 2, which does not contain a STAT1 response 287 
element and represents a non-specific region in the CFB promoter (Figure 288 
4D). No STAT1 protein was enriched in the second region. 289 
 290 
3. STAT1 mediates PC1-CTT induced CFB expression  291 
To test whether PC1 C-terminal tail (PC1-CTT) regulates CFB expression, a 292 
soluble PC1-CTT was over-expressed in UCL93 renal epithelial cells. 293 
PC1-CTT increased CFB expression which was correlated with enhanced 294 
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phosphorylation of JAK2 and STAT1 in renal epithelial cells (Figure 5A).   295 
We next tested whether the PC1-CTT induced expression of CFB requires 296 
STAT1, PC1-CTT transfected renal epithelial cells were treated with 297 
fludarabine. The STAT1 inhibitor fludarabine suppressed PC1-CTT induced 298 
CFB overexpression and p-STAT1 up-regulation in renal epithelial cells 299 
(Figure 5B).   300 
Mutation of the STAT1 binding site significantly down-regulated the 301 
PC1-CTT induced CFB promoter activity in UCL93 cells by 29% (Figure 302 
6A), which suggests that the STAT1 response element at −219 to −210 is 303 
important for PC1-CTT mediated transactivation of CFB promoter.  304 
To further investigate the mechanism of STAT1 regulation of CFB 305 
expression, PC1-CTT plasmid was co-transfected with two different 306 
dominant-negative (DN) STAT1 plasmids (DN1-STAT1 with Y701F 307 
mutation or DN2-STAT1 with S727A mutation). DN1-STAT1 and 308 
DN2-STAT1 significantly suppressed PC1-CTT induced CFB promoter 309 
activity as compared with PC1-CTT and empty vector co-transfected cells 310 
(Figure 6B). Furthermore, we showed that CFB reporter gene and GAS 311 
reporter gene have similarly increased responses to PC1-CTT stimulation, 312 
and that the GAS mutation abolished the response of GAS reporter gene to 313 
PC1-CTT stimulation (Figure 6C). Taken together our data indicate that 314 
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PC1-CTT is capable of activating CFB transcription through the promoter 315 
element in the region −219 to −210 which contains the STAT1 binding site. 316 
 317 
4. PC1-CTT stimulates macrophage differentiation through STAT1 and 318 
CFB 319 
To study whether CFB triggers macrophage M2 phenotype differentiation, 320 
bioactive human CFB was used to treat RAW264.7 mouse macrophage cells. 321 
Figure 7A shows that human CFB dose-dependently up-regulated the M2 322 
marker arginase-1 (Arg1) in mouse macrophages from 30 ng/ml to 100 323 
ng/ml, and the expression of M1 phenotype marker iNOS was not changed 324 
by CFB stimulation. RT-PCR was performed to further analyze macrophage 325 
differentiation. Figure 8A shows that the M2 marker Arg1 but not Mrc1 was 326 
increased by CFB treatment. However, CFB induced M2 macrophages had 327 
lower Arg1 expression as compared with typical M2 macrophages induced 328 
by IL4/IL13. Again, the mRNA expression of the M1 markers iNOS or TNF-329 
ɑ was not up-regulated by CFB treatment (Figure 8B). Moreover, CFB 330 
antibody was included in conditioned medium that was generated from renal 331 
epithelial cells transfected with PC1-CTT (PC1-CTT-CM). Treatment of 332 
RAW264.7 cells with the conditioned media from PC1-CTT over- 333 
expressing renal epithelial cells markedly increased the protein level of 334 
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arginase-1 but not iNOS, whereas CFB antibody neutralization in 335 
PC1-CTT-CM suppressed arginase-1 expression in Raw 264.7 macrophage 336 
cells dose-dependently (Figure 7B). RT-PCR analysis showed that PC1-CTT 337 
conditioned media induced significantly higher expression of the M2 338 
markers Arg1 and Mrc1, but did not induce M1 macrophage differentiation 339 
(Figure 8C and 8D). Interestingly, PC1-CTT induced similar level of Arg1 340 
expression but less Mrc1 expression as compared with IL4/IL13 induced M2 341 
macrophages (Figure 8C). 342 
To explore the role of STAT1 in renal epithelial cell induced M2 macrophage 343 
differentiation, we generated conditioned medium from renal epithelial cells 344 
which were treated with STAT1 specific inhibitor fludarabine. Figure 7C 345 
shows that STAT1 inhibition in renal epithelial cells reduced arginase-1 346 
expression by macrophages in a dose-dependent manner. Moreover, STAT1 347 
inhibition by fludarabine in renal epithelial cells suppressed arginase-1 348 
expression induced by PC1-CTT-CM (Figure 7D). 349 
Taken together our data suggest that PC1-CTT induced macrophage 350 
activation into an M2 phenotype is mediated by STAT1 and CFB. 351 
 352 
5. NF-κB partly mediates PC1-CTT induced CFB expression  353 
To test whether the NF-κB pathway partly mediates PC1-CTT induced CFB 354 
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expression, we first treat renal epithelial cells with the NF-κB inhibitor 355 
quinazoline (6-amino-4-(4-phenoxypheny lethylamino; QNZ). Figure 9A 356 
shows that QNZ dose-dependently down-regulated CFB expression which 357 
was correlated with down-regulation of p50/p65 NF-κB. Second, PC1-CTT 358 
induced up-regulation of p50/p65 NF-κB and CFB, and QNZ 359 
down-regulated p50/p65 and CFB expression (Figure 9B). Third, we found 360 
that CFB promoter activity triggered by PC1-CTT was reduced by NF-κB 361 
inhibitor QNZ (Figure 9C).  362 
 363 
364 
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Discussion: 365 
We previously showed that CFB is up-regulated and plays an important role 366 
in human ADPKD and in the Han:SPRD rat model of PKD, however the 367 
mechanism of CFB overexpression in PKD is not known (13, 14). Huang et 368 
al. showed that STAT1 mediates IFN-γ induced mouse CFB expression 369 
through direct interaction with murine CFB promoter (7). Therefore we 370 
hypothesized that STAT1 regulates CFB expression in PKD. In this study, 371 
we proved this hypothesis by showing that 1) STAT1 activation correlated 372 
with CFB expression in rat and human cystic kidney tissues; 2) 373 
over-expression of STAT1 in renal epithelial cells increased CFB expression; 374 
3) STAT1 inhibition by fludarabine reduced CFB expression; 4) STAT1 375 
over-expression enhanced CFB promoter activity, and a mutation of the 376 
STAT1 binding site on CFB promoter abolished this effect; 5) STAT1 377 
interacted with human CFB promoter.  378 
It is known that the cytoplasmic tail of polycystin-1 can be cleaved into a 30 379 
KD soluble peptide (PC1-CTT) which can function as a co-transcriptional 380 
factor entering the cell nucleus and regulating down-stream gene expression 381 
(2, 4, 18). Moreover it was shown that PC1-CTT increases STAT1 382 
transcriptional activity (18). Therefore we hypothesized that PC1-CTT 383 
up-regulates CFB expression through STAT1 in PKD. Here we showed that 384 
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the PC1-CTT over-expression correlated with JAK2 and STAT1 activation in 385 
human and rat polycystic kidneys where CFB was abnormally up-regulated. 386 
Secondly, PC1-CTT over-expression in renal epithelial cells activated 387 
JAK2/STAT1 pathway and led to up-regulation of CFB. Finally, STAT1 388 
inhibition abolished PC1-CTT induced CFB expression and CFB promoter 389 
activation.  390 
Interestingly, we found that mutation of the STAT1 binding site only partly 391 
abolished PC1-CTT triggered CFB promoter activity, whereas the mutant 392 
promoter completely blocked STAT1 induced CFB promoter activation. 393 
These data suggest that a fraction of the PC1-CTT effect on CFB promoter is 394 
independent of STAT1. It has been shown that NF-κB could regulate CFB 395 
expression, and that the NF-κB pathway is activated in cystic kidneys (12, 396 
16). We therefore postulated that NF-κB could partly mediate PC1-CTT 397 
induced CFB expression. We proved this by showing that 1) NF-κB inhibitor 398 
QNZ down-regulated CFB expression in renal epithelial cells; 2) the reporter 399 
activity driven by PC1-CTT can be reduced by NF-κB inhibitor QNZ; 3) 400 
PC1-CTT induced up-regulation of p50/p65 NF-κB and CFB, and moreover 401 
QNZ down-regulated p50/p65 and CFB expression. 402 
The role of STAT1 in PKD is not completely studied. It has been shown that 403 
polycystin-1 induces cell cycle arrest through STAT1 activation, suggesting 404 
 23 
 
an anti-proliferative and therefore a protective role of STAT1 in PKD (3). 405 
However, our data showed that STAT1 mediates PC1-CTT induced CFB 406 
expression and macrophage differentiation in vitro. We further confirmed the 407 
correlation of STAT1 activation and CFB expression in human and rat 408 
polycystic kidneys. In liver disease, IFN-γ activation of STAT1 induces 409 
apoptosis-associated liver inflammation (5). Interestingly, in a 410 
non-orthologous PKD mouse model, where PC1 tail is over-expressed, 411 
IFN-γ challenge resulted in a strong STAT1 activation and increased 412 
apoptosis level. These data suggests a pro-inflammatory role of STAT1 in 413 
PKD. Therefore an in vivo study should be performed with STAT1 inhibitor 414 
or by STAT1 gene depletion to confirm its role in PKD. 415 
Macrophages which have infiltrated the cystic kidneys present with a special 416 
M2 phenotype which is characterized by highly increased arginase-1 417 
expression and slightly increased Mrc1 expression (15). Our study suggests 418 
that PC1-CTT and CFB participate in cystic M2 macrophage differentiation. 419 
First, with different M1 or M2 markers and with two different approaches, 420 
we showed that PC1-CTT or CFB promoted macrophage M2 but not M1 421 
phenotype conversion. Second, PC1-CTT or CFB stimulated arginase-1 422 
expression but not or to a lesser degree Mrc1 expression which is consistent 423 
to the cystic M2 phenotype. Interestingly, compared with IL4/IL13 induced 424 
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conventional M2 macrophages, PC1-CTT stimulated similar levels of 425 
argniase-1 expression but decreased levels of Mrc1 expression, whereas 426 
CFB triggered macrophages had much less arignase-1 expression and Mrc1 427 
expression. These data suggest that there are other un-defined factors, 428 
different from CFB that participate in PC1-CTT induced macrophage 429 
differentiation. 430 
The M2 macrophages that infiltrate the cystic kidney may promote cyst 431 
expansion by directly or indirectly stimulating cyst epithelial cell 432 
proliferation (15, 16). We showed that conditioned media derived from 433 
STAT1-inhibited renal epithelial cells retarded macrophage M2 434 
differentiation. Therefore STAT1 may also play a proliferative role in 435 
ADPKD through activating macrophage. 436 
The overexpression of PC1-CTT is observed in human ADPKD and also in 437 
non-orthologous animal models of PKD (18). Ureteral ligation also induced 438 
up-regulation of PC1-CTT in non-mutated kidney suggesting that alteration 439 
of tubular fluid flow triggers the cleavage of cytoplasmic tail from the 440 
mechanical sensor polycystin-1 (4). In this study we found a novel function 441 
of PC1-CTT in PKD inflammation, namely increased CFB expression in 442 
renal epithelial cells and modulated macrophage differentiation. Interestingly, 443 
we found PC1-CTT and CFB strongly expressed in small cysts. It has been 444 
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shown that in ADPKD kidney tissues, macrophages localize mostly adjacent 445 
to renal cysts or even infiltrate small cysts (15). Thus it could be speculated 446 
that the change of tubular fluid flow by expanding renal cysts initiates 447 
inflammation through increasing cleavage of polycystin-1 and this might 448 
lead to the genesis of new cysts. 449 
 450 
In summary, our study showed that CFB over-expression in PKD is caused 451 
at least in part by PC1-CTT induced STAT1 activation, and by activation of 452 
the NF-κB pathway. STAT1 could be a new target to prevent PKD 453 
inflammation.   454 
455 
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 529 
Figure Legends 530 
Figure 1 531 
PC1-CTT, p-JAK2, p-STAT1 and CFB expression in PKD. A. 532 
Phosphorylated JAK2, total JAK2, phosphorylated STAT1, total STAT1, 533 
CFB and PC1-CTT in control and human ADPKD kidneys were analysed by 534 
Western blot, and then quantified by densitometry. Representative Western 535 
blot is shown, and results represent an average of three independent. B. 536 
Phosphorylated JAK2, total JAK2, phosphorylated STAT1, total STAT1, 537 
CFB and PC1-CTT in +/+ and Cy/+ Han:SPRD rat  kidneys were analysed 538 
by Western blot, and then quantified by densitometry. Representative 539 
Western blot is shown, and results represent an average of three independent. 540 
C. Immunohistochemistry staining of phosphorylated JAK2, phosphorylated 541 
STAT1, CFB and PC1-CTT in Han:SPRD rat kidneys are shown. One 542 
representative of three independent experiments is shown, bars = 40μm. Not 543 
significant (NS), *P < 0.05, **P < 0.01, ***P < 0.001.  544 
 545 
Figure 2 546 
Specificity of polycystin-1 antibody for PC1-CTT. The expression of 547 
PC1-CTT in Pkd1+/-, Pkd1-/-, UCL93 control and PC1-CTT overexpressing 548 
 30 
 
UCL93 cells. PC1-CTT was detected by the polycystin-1 (PC1) or myc 549 
antibody. Blots were quantified by densitometry, and the average 550 
densitometry values from three independent experiments is shown. **P < 551 
0.01, ***P < 0.001. One representative of three independent experiments is 552 
shown. 553 
 554 
Figure 3 555 
The effect of STAT1 on CFB expression. A. CFB expression in STAT1 556 
over-expressed UCL93 renal epithelial cells 48hr after transfection. Blots 557 
were quantified by densitometry, and the average densitometry values from 558 
three independent experiments is shown. B. CFB expression in renal 559 
epithelial cells which were treated with the STAT1 inhibitor fludarabine for 560 
48hr. Blots were quantified by densitometry, and the average densitometry 561 
values from three independent experiments is shown. Not significant (NS), 562 
*P < 0.05, **P < 0.01, ***P < 0.001. One representative Western blot of 563 
three independent experiments is shown.  564 
 565 
Figure 4 566 
A. The representation of CFB promoter with putative STAT binding site 567 
(−219/-210). B. Luciferase activity of CFB promoter (CFB-Pr) or mutated 568 
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CFB promoter (CFB-Pr-Mut) were measured in control or STAT1 569 
transfected UCL93 cells. C. Luciferase activity of CFB promoter (CFB-Pr), 570 
GAS promoter (GAS-Pr) or mutated GAS promoter (GAS-Pr-Mut) were 571 
measured in control or STAT1 transfected UCL93 cells. D. ChIP assay was 572 
conducted on 293T cells transfected with control or STAT1. Two different 573 
regions (−700/-350, -400/-100) were amplified by PCR after chromatin 574 
immunoprecipitation using anti- STAT1 antibody. Not significant (NS), **P 575 
< 0.01. One representative of three independent experiments is shown. 576 
 577 
Figure 5 578 
The effect of PC1-CTT on JAK2/STAT1 activation and CFB expression. A. 579 
JAK2/STAT1 activation and CFB expression in UCL93 renal epithelial cell 580 
lines after 48hr PC1-CTT transfection. Blots were quantified by 581 
densitometry, and the average densitometry values from three independent 582 
experiments is shown. B. PC1-CTT was transfected in renal epithelial cells 583 
and followed by 24hr fludarabine treatment, CFB expression was analysed 584 
by Western blot and then quantified by densitometry. The average 585 
densitometry values from three independent experiments is shown. Not 586 
significant (NS), *P<0.05, **P < 0.01, ***P < 0.001. One representative 587 
Western blot of three independent experiments is shown. 588 
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 589 
Figure 6 590 
A. Luciferase activity of CFB promoter (CFB-Pr) or mutated CFB promoter 591 
(CFB-Pr-Mut) were measured in control or PC1-CTT transfected renal 592 
epithelial cells. B. Co-transfection of renal epithelial cells with DN-STAT1 593 
(DN1-STAT1 or DN2-STAT1) attenuated PC1-CTT induced CFB promoter 594 
activity. C. Luciferase activity of CFB promoter (CFB-Pr), GAS promoter 595 
(GAS-Pr) or mutated GAS promoter (GAS-Pr-Mut) were measured in 596 
control or PC1-CTT transfected UCL93 cells. Not significant (NS), *P<0.05, 597 
**P < 0.01. One representative of three independent experiments is shown. 598 
 599 
Figure 7 600 
PC1-CTT promotes RAW264.7 macrophages toward M2 phenotype 601 
differentiation through STAT1 and CFB. A. Bioactive human CFB was 602 
added into un-conditioned media to treat macrophages. The expression of 603 
macrophage M1 phenotype marker iNOS and M2 phenotype marker 604 
arginase-1 were examined by Western blot. Blots were quantified by 605 
densitometry, and the average densitometry values from three independent 606 
experiments is shown. B. Conditioned media were prepared from control 607 
(Control-CM) or PC1-CTT (PC1-CTT-CM) transfected renal epithelial cells. 608 
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Isotype IgG or CFB antibody was added to treat macrophages. C. 609 
Conditioned media were generated from renal epithelial cells treated with 610 
fludarabine and used to treat macrophages for 24hr. D. PC1-CTT was 611 
transfected in renal epithelial cells and followed by fludarabine treatment, 612 
and conditioned media were collected to treat macrophages. *P < 0.05, **P 613 
< 0.01, ***P < 0.001. One representative of three independent experiments 614 
is shown. 615 
 616 
Figure 8 617 
PC1-CTT promotes differentiation of RAW264.7 macrophages towards M2 618 
phenotype through CFB. A and B. Bioactive human CFB was added into 619 
un-conditioned media to treat macrophages. IFN-γor IL4/IL13 was used as 620 
a positive control to induce M1 or M2 macrophage phenotype, respectively. 621 
The expression of macrophage M1 phenotype markers iNOS or TNF-ɑ, and 622 
M2 phenotype markers arginase-1 (Arg1) or Mrc1 were examined by 623 
RT-PCR. C and D. Conditioned media were collected from control 624 
(Control-CM) or PC1-CTT (PC1-CTT-CM) transfected renal epithelial cells 625 
to treat macrophages, then M1/M2 markers were analysed by RT-PCR. Not 626 
significant (NS), *P < 0.05, ***P < 0.001. One representative of three 627 
independent experiments is shown. 628 
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 629 
Figure 9 630 
NF-κB mediates PC1-CTT induced CFB expression. A. NF-κB (p50 and p65) 631 
and CFB expression in renal epithelial cells which were treated with the 632 
NF-κB inhibitor QNZ for 48 hr. B. PC1-CTT was transfected in renal 633 
epithelial cells and followed by 24 hr QNZ treatment, NF-κB (p50 and p65) 634 
and CFB expression were analysed by Western blot. Blots were quantified 635 
by densitometry, and the average densitometry values from three 636 
independent experiments is shown. C. Luciferase activity of CFB promoter 637 
(CFB-Pr) was measured in control or PC1-CTT transfected renal epithelial 638 
cells or QNZ treated PC1-CTT transfected cells. *P < 0.05, **P < 0.01, ***P 639 
< 0.001. One representative of three independent experiments is shown. 640 
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